SGLT2 inhibitors are recognized for their cardioprotective and nephroprotective properties, thus making them particularly advantageous for patients at high risk of cardiovascular diseases and those suffering from chronic kidney disease (Zelniker et al., 2019; Rahman et al., 2023). The gene discussed is SLC5A2; the disease is chronic kidney disease.